Cervical Cancer, HPV, and Immune Clearance
Cervical cancer is caused by persistent human papillomavirus (HPV) infection in immunologically susceptible women. Most HPV infections are cleared by an intact immune response within 2 years; persistent infection leading to carcinogenesis depends on immune function. Environmental immunosuppressants including PFAS that impair HPV clearance could increase cervical cancer risk beyond HPV exposure alone.
PFAS Immunosuppression and HPV Persistence
PFAS suppress natural killer cell activity and cytotoxic T-cell function—immune effectors critical for HPV-infected cell elimination. Studies show higher PFAS serum levels in women with persistent HPV infection compared to those who cleared infection, consistent with PFAS-mediated impairment of viral immune clearance mechanisms.
HPV Vaccination Response
PFAS-induced vaccine response suppression documented for other vaccines likely extends to HPV vaccination. Lower HPV vaccine antibody titers in PFAS-exposed individuals may reduce vaccine efficacy, partially undermining cervical cancer prevention programs in PFAS-contaminated communities.
Public Health Integration
Cervical cancer prevention programs in PFAS-contaminated communities should consider enhanced screening protocols alongside vaccination efforts. PFAS-aware immune support—including reduction of ongoing PFAS exposure—may complement vaccination and screening strategies in communities with both high PFAS exposure and HPV prevalence